Featured Research

from universities, journals, and other organizations

Cleverly designed vaccine blocks H5 avian influenza in animal models

Date:
March 25, 2013
Source:
American Society for Microbiology
Summary:
Until now, most experimental vaccines against the highly lethal H5N1 avian influenza virus have lacked effectiveness. But a new vaccine has proven highly effective against the virus when tested in both mice and ferrets. It is also effective against the H9 subtype of avian influenza.

Until now most experimental vaccines against the highly lethal H5N1 avian influenza virus have lacked effectiveness. But a new vaccine has proven highly effective against the virus when tested in both mice and ferrets. It is also effective against the H9 subtype of avian influenza. The research is published online ahead of print in the Journal of Virology.

The strength of the new vaccine is that it uses attenuated, rather than "killed" virus. (Killed viruses are broken apart with chemicals or heat, and they are used because they are safer than attenuated viruses.) Killed virus vaccines against avian influenza are injected into the bloodstream, whereas this vaccine is given via nasal spray, thus mimicking the natural infection process, stimulating a stronger immune response.

The danger of current attenuated virus vaccines is that they might exchange dangerous genetic material with garden variety influenza viruses of the sort that strike annually, potentially rendering a lethal but very hard to transmit influenza virus, such as H5, easily transmissible among humans. To mitigate those dangers, the study authors, led by Daniel Perez of the University of Maryland, came up with an ingenious design. Influenza viruses carry their genetic material in eight "segments," explains coauthor and University of Maryland colleague Troy Sutton. When viruses reassort, they exchange segments. But each segment is unique, all eight are needed, and the viruses are unfit if they contain more than eight segments.

The vaccine is based on an attenuated version of the H9 virus, with an H5 gene added into one of the H9 virus' segments, to confer immunity to the H5 virus. Segment 8, which is composed of the so-called NS1 and NS2 genes, was split apart, and the NS2 gene was moved into segment 2, adjacent to the polymerase gene, which copies the virus' genetic material during replication. Placing NS2 next to the polymerase gene slowed its function, interfering with the virus' replication. That makes the vaccine safer.

The next step was to engineer the H5 gene into the vaccine. It was inserted into segment 8, where the NS2 gene had been.

Another aspect of the new vaccine's design makes it safer still, by rendering successful reassortment less likely. Both NS1 and NS2 are needed for viral replication. Since the two genes are now separated into different segments, any reassortment will have to include both segments, instead of just segment 8, in order for a reassortant virus to be viable. This greatly reduced the probability of successful reassortment.

The World Health Organization (WHO) recognizes avian influenza subtypes H5, H7, and H9 as potential pandemic viruses, because they all have in rare instances infected humans, and because they circulate in wild birds. Single reassortants could be sufficient to breach the species barrier, and since they do not circulate among us, we lack any immunity. Moreover, H5 is unusually lethal, having killed roughly half of those few it is confirmed to have infected.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. Pena, T. Sutton, A. Chockalingam, S. Kumar, M. Angel, H. Shao, H. Chen, W. Li, D. R. Perez. Influenza viruses with rearranged genomes as live-attenuated vaccines. Journal of Virology, 2013; DOI: 10.1128/JVI.02490-12

Cite This Page:

American Society for Microbiology. "Cleverly designed vaccine blocks H5 avian influenza in animal models." ScienceDaily. ScienceDaily, 25 March 2013. <www.sciencedaily.com/releases/2013/03/130325125649.htm>.
American Society for Microbiology. (2013, March 25). Cleverly designed vaccine blocks H5 avian influenza in animal models. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/03/130325125649.htm
American Society for Microbiology. "Cleverly designed vaccine blocks H5 avian influenza in animal models." ScienceDaily. www.sciencedaily.com/releases/2013/03/130325125649.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins